1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow full-course immunotherapy: new trials by email Literature Review of full-course immunotherapy trials Research Report on full-course immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC Induction chemoimmunotherapy, radiotherapy, Concurrent Chemotherapy - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 256 | 2026-10-12 | 2026-10-14 |
| Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy Blinatumomab and Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia, Immunotherapy | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 26 | 2025-05-17 | 2026-03-24 |
Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Sun Yat-sen University (1) · The First Affiliated Hospital of Soochow University (1)
China (2)
Hui Liu (1) · Sheng-Li Xue, M.D. (1)